BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 38428265)

  • 1. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
    Provencio-Pulla M; Pérez-Parente D; Olson S; Hasan H; Balea BC; Rodríguez-Abreu D; Piqueras ML; Pal N; Wilkinson S; Vilas E; Ruiz-Gracia P; Cobo-Dols M
    Clin Transl Oncol; 2024 Jun; 26(6):1384-1394. PubMed ID: 38183584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
    Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
    Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
    Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
    Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
    Iams WT; Yu H; Shyr Y; Patil T; Horn L; McCoach C; Kelly K; Doebele RC; Camidge DR
    Clin Lung Cancer; 2018 Nov; 19(6):531-543. PubMed ID: 30197261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LKB1 gene mutations in Japanese lung cancer patients.
    Onozato R; Kosaka T; Achiwa H; Kuwano H; Takahashi T; Yatabe Y; Mitsudomi T
    Cancer Sci; 2007 Nov; 98(11):1747-51. PubMed ID: 17711506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
    Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
    Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
    Qian Y; Galan-Cobo A; Guijarro I; Dang M; Molkentine D; Poteete A; Zhang F; Wang Q; Wang J; Parra E; Panda A; Fang J; Skoulidis F; Wistuba II; Verma S; Merghoub T; Wolchok JD; Wong KK; DeBerardinis RJ; Minna JD; Vokes NI; Meador CB; Gainor JF; Wang L; Reuben A; Heymach JV
    Cancer Cell; 2023 Jul; 41(7):1363-1380.e7. PubMed ID: 37327788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
    Svensson RU; Parker SJ; Eichner LJ; Kolar MJ; Wallace M; Brun SN; Lombardo PS; Van Nostrand JL; Hutchins A; Vera L; Gerken L; Greenwood J; Bhat S; Harriman G; Westlin WF; Harwood HJ; Saghatelian A; Kapeller R; Metallo CM; Shaw RJ
    Nat Med; 2016 Oct; 22(10):1108-1119. PubMed ID: 27643638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
    Ricciuti B; Garassino MC
    J Thorac Oncol; 2024 Jun; 19(6):877-882. PubMed ID: 38849167
    [No Abstract]   [Full Text] [Related]  

  • 11. Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.
    Li L; He K; Zhou T; Xu Y; Pang J; Yu Q; Gao Y; Shi H; Zhu H; Li M; Yu J; Yuan S
    Mol Oncol; 2024 Jun; 18(6):1649-1664. PubMed ID: 38327028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence Study of Patients with
    Anttalainen A; Pietarinen P; Tuominen S; Mattila R; Mutka A; Knuuttila A
    Curr Oncol; 2024 May; 31(5):2700-2712. PubMed ID: 38785486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
    Gao Y; Ge G; Ji H
    Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
    [TBL]